García-Rojas Leonardo, Adame-Ocampo Gloria, Alexánderson Erick, Tovilla-Canales José Luis
Instituto de Oftalmología "Fundación de Asistencia Privada Conde de Valenciana I.A.P.", 06800 Mexico City, DF, Mexico.
J Ophthalmol. 2013;2013:529187. doi: 10.1155/2013/529187. Epub 2013 Feb 14.
Objective. To compare 18-fluorodeoxyglucose (FDG) uptake by positron emission tomography (PET) in extraocular muscles (EOMs) of patients with Graves' ophthalmopathy (GO) versus patients without GO. Design. Prospective, observational, comparative, and cross-sectional study. Participants. Thirty-two eyes of patients with GO and seventy eyes of patients without GO. Methods. We prospectively included patients older than 18 years of age with and without GO. FDG-PET imaging study was performed; standardized unit value (SUVmax) was quantified in EOMs. Standard deviation and significant statistical difference (P < 0.05) were calculated. Results. Thirty-two eyes of sixteen patients of the GO group were included, with a mean age of 44.31 (20-71) years. Seventy eyes of thirty-five patients of the group without GO were included, with a mean age of 49.20 (24-77) years. EOMs average uptake of the groups with and without GO were 3.38 ± 1.31 and 1.89 ± 0.51 SUVmax (P < 0.05), respectively. Conclusion. FDG uptake was significantly increased in EOMs of patients with GO. PET gives valuable information and may be a helpful tool in detecting, localizing, and quantifying GO inflammation. Further research is needed to define the role of PET in detecting, grading, and following up GO in order to optimize treatment in the inflammatory stage.
目的。比较格雷夫斯眼病(GO)患者与非GO患者眼外肌(EOM)中18-氟脱氧葡萄糖(FDG)通过正电子发射断层扫描(PET)的摄取情况。设计。前瞻性、观察性、比较性和横断面研究。参与者。32只GO患者的眼睛和70只非GO患者的眼睛。方法。我们前瞻性纳入了年龄大于18岁的有或无GO的患者。进行了FDG-PET成像研究;在EOM中对标准化摄取值(SUVmax)进行定量。计算标准差和显著统计学差异(P<0.05)。结果。GO组16例患者的32只眼睛被纳入,平均年龄为44.31(20-71)岁。非GO组35例患者的70只眼睛被纳入,平均年龄为49.20(24-77)岁。有和无GO组的EOM平均摄取量分别为3.38±1.31和1.89±0.51 SUVmax(P<0.05)。结论。GO患者的EOM中FDG摄取显著增加。PET提供了有价值的信息,可能是检测、定位和量化GO炎症的有用工具。需要进一步研究来确定PET在检测、分级和随访GO中的作用,以便在炎症阶段优化治疗。